Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) EBITDA (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of EBITDA readings, the most recent being -$10.1 million for Q1 2026.

  • Quarterly EBITDA fell 30.98% to -$10.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$35.1 million through Mar 2026, down 30.33% year-over-year, with the annual reading at -$32.7 million for FY2025, 34.03% down from the prior year.
  • EBITDA hit -$10.1 million in Q1 2026 for DiaMedica Therapeutics, down from -$8.7 million in the prior quarter.
  • Across five years, EBITDA topped out at -$3.1 million in Q3 2022 and bottomed at -$10.1 million in Q1 2026.
  • Average EBITDA over 5 years is -$5.9 million, with a median of -$5.2 million recorded in 2024.
  • The largest annual shift saw EBITDA rose 11.53% in 2022 before it crashed 58.27% in 2024.
  • DiaMedica Therapeutics' EBITDA stood at -$3.7 million in 2022, then tumbled by 37.26% to -$5.0 million in 2023, then tumbled by 58.27% to -$8.0 million in 2024, then decreased by 9.83% to -$8.7 million in 2025, then decreased by 15.77% to -$10.1 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's EBITDA are -$10.1 million (Q1 2026), -$8.7 million (Q4 2025), and -$8.6 million (Q3 2025).